Analyst Price Targets — TTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 7:47 am | Ryan Deschner | Raymond James | $10.00 | $9.26 | StreetInsider | Raymond James Upgrades Tvardi Therapeutics Inc (TVRD) to Outperform |
| June 30, 2026 1:32 pm | — | Northland Securities | $14.00 | $11.43 | TheFly | Tetra Technologies price target raised to $14 from $11.50 at Northland |
| January 12, 2026 10:48 am | Stephen Gengaro | Stifel Nicolaus | $13.00 | $9.87 | StreetInsider | TETRA Technologies Inc. (TTI) PT Raised to $13 at Stifel, 'remains a favorite name' |
| December 31, 2025 2:32 pm | — | Northland Securities | $11.50 | $9.44 | TheFly | Tetra Technologies price target raised to $11.50 from $8.50 at Northland |
| October 30, 2025 12:33 pm | Bobby Brooks | Northland Securities | $8.50 | $7.01 | TheFly | Tetra Technologies price target raised to $8.50 from $8 at Northland |
| October 15, 2025 10:53 am | Stephen Gengaro | Stifel Nicolaus | $9.00 | $7.04 | TheFly | Tetra Technologies price target raised to $9 from $6.50 at Stifel |
| September 26, 2025 1:25 pm | — | Northland Securities | $7.00 | $6.02 | TheFly | Tetra Technologies price target raised to $7 from $5.50 at Northland |
| April 15, 2025 12:25 pm | Stephen Gengaro | Stifel Nicolaus | $6.50 | $2.30 | TheFly | Tetra Technologies price target lowered to $6.50 from $7 at Stifel |
| June 14, 2022 11:15 am | Tim Moore | EF Hutton | $8.00 | $4.84 | Pulse 2.0 | TETRA Technologies (TTI) Stock Price: $8 Target And Buy Rating |
Latest News for TTI
SPRING, Texas, July 13, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE:TTI) will release Second Quarter 2026 results after the market closes on August 3, 2026 and will host a conference call to discuss the results and outlook on August 4, 2026, at 10:30am ET. CLICK HERE to pre-register and obtain your dial in number and passcode.
San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing novel sulfur-based thiol therapies for rare pediatric, metabolic and mitochondrial disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to…
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7 th , at 8:30am ET HOUSTON, July…
Tetra Technologies (TTI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TTI.
U.S. House Trading
No House trades found for TTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.